O'Day, S <br/><br/>
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma.  [electronic resource] 

 -  British journal of cancer  Jul 2011 
 - 346-52 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2011.183  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Dacarbazine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Integrin alphaV--immunology<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Skin Neoplasms--drug therapy<br/>Uveitis--chemically induced